A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
Completed · Phase 1 · NCT07007091
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $1.6M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 260
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug), Risankizumab (drug)
- Dates
- Started 2025-06-12; completion 2026-01-15
- Results posted
- Not yet
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
From ClinicalTrials.gov, last updated 2026-01-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.6M in research payments for this study in 2025 (18 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Pharmacology of Miami Inc $1.6M
- $740
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.